首页> 外文期刊>Analytical methods >A simple, sensitive, high-resolution, customized, reverse phase ultra-high performance liquid chromatographic method for related substances of a therapeutic peptide (bivalirudin trifluoroacetate) using the quality by design approach
【24h】

A simple, sensitive, high-resolution, customized, reverse phase ultra-high performance liquid chromatographic method for related substances of a therapeutic peptide (bivalirudin trifluoroacetate) using the quality by design approach

机译:一种简单,灵敏,高分辨率,定制,反相超高效液相色谱法,用于使用设计方法使用质量的治疗肽(Bivalirudin三氟乙酸盐)的相关物质

获取原文
获取原文并翻译 | 示例
           

摘要

Among all chemical sameness characterization tests of Therapeutic Peptides (TPs), one of the most significant and challenging aspects is to demonstrate comparable impurity profiles (both qualitative & quantitative) between a generic product and reference listed drug (RLD). Though multiple state of the art orthogonal analytical methods are being used for the identification and quantification of related impurities in TPs, it is important that the developed methods are simple, selective, and sensitive, and can be easily implementable in quality control laboratories. The current published chromatographic (HPLC or UHPLC) methods for the quantification of related substances in TPs rarely use non-mass spectrometry compatible ion pairing reagents (NMS-IPRs) in the mobile phase composition over mass spectrometry compatible ion pairing reagents (MS-IPRs), due to their compatibility issues with high-resolution mass-based detection methods. We hypothesize that achieving mixed mode stationary phase characteristics using hydrophobic NMS-IPRs such as sodium 1-butanesulfonate, at concentrations <10 mM in the diethanolammonium phosphate buffer (pH 2.9) on a C-18 stationary phase, would be able to resolve critical impurities such as Penta-Gly, D-Asn, and Tri-Gly using the single UHPLC method, and is also selective to all other related impurities of bivalirudin (BIV) cited in the literature. Furthermore, customization of column dimensions (300 mm x 2.1 mm x 1.8 mu m) helped in achieving a resolution (Rs) > 2.0 between Penta-Gly & BIV, and a peak to valley ratio (Hp/Hv) > 4.0 between BIV & D-Asn and D-Asn & Tri-Gly impurities. The developed method is sensitive (LOQ similar to 0.05% with respect to analyte concentration), precise, accurate, and linear in the range of 1 mu g mL(-1) to 2500 mu g mL(-1). This method is rugged, robust, and easily implementable in quality control laboratories for monitoring the related impurities of bivalirudin.
机译:在治疗性肽(TPS)的所有化学品鉴定试验中,最重要和最具挑战性的方面之一是在通用产品和参考列出的药物(RLD)之间表现出可比的杂质谱(定性和定量)。虽然多种最新的正交分析方法用于TPS中相关杂质的鉴定和定量,但重要的是,开发方法简单,选择性和敏感,并且可以在质量控制实验室中容易地实现。用于定量TPS中的相关物质的目前发表的色谱(HPLC或UHPLC)方法很少在流动相组合物中使用非质谱相容的离子配对试剂(NMS-IPRS)在质谱上相容离子配对试剂(MS-IPRS) ,由于其具有高分辨率基于群众的检测方法的兼容性问题。我们假设使用疏水性NMS-IPR(例如1-丁磺酸钠)在C-18固定相的浓度<10mM)中使用疏水NMS-IPR等疏水NMS-IPR(PH 2.9)的浓度<10mM的混合模式固定相位特征,将能够解决关键的杂质如Penta-Gly,D-ASN和三脂使用单个UHPLC方法,也选择于文献中引用的Bivalirudin(BIV)的所有其他相关杂质。此外,柱尺寸的定制(300mm×2.1mm×1.8μm)有助于在Penta-gly和BIV之间实现分辨率(Rs)> 2.0,以及BIV& D-ASN和D-ASN&Tri-Gly杂质。开发方法是敏感的(LOQ相对于分析物浓度的0.05%),精确,精确,并且在1μgmm(-1)至2500μg(-1)的范围内。这种方法在质量控制实验室中坚固,稳健,并且容易可实现,用于监测BivalIrudin的相关杂质。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号